BPC-157 (body protection compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has circulated through sports medicine, peptide clinics, and recovery communities for years on the strength of compelling animal data: accelerated tendon-to-bone healing, angiogenesis, counteraction of NSAID and corticosteroid gut damage, and modulation of growth factor pathways including VEGF and FAK-paxillin.

Human randomized controlled trial evidence remains limited. BPC-157 is not FDA-approved for any indication. Compounded injectable and oral forms exist in 503A pharmacy practice, often dosed at 250 to 500 mcg daily subcutaneously near injury sites or systemically in the abdomen. Patients considering BPC-157 need a clear-eyed view of what is established in animals, what is anecdotal in humans, and what regulatory status implies.

Origin and mechanism

BPC-157 is a fragment of larger gastric juice proteins involved in mucosal defense. The peptide appears to stabilize endothelial cells, promote nitric oxide-mediated vasodilation, upregulate growth hormone receptors in tendon fibroblasts, and protect against oxidative stress in multiple tissue models.

Preclinical studies in rats demonstrate faster healing of transected Achilles tendons, improved recovery from inflammatory bowel injury, and protection against alcohol and NSAID-induced gastric lesions. The mechanism is pleiotropic rather than single-target, which makes mechanistic purity difficult but may explain broad tissue effects in animal models.

Routes of administration

Subcutaneous injection near the site of musculoskeletal injury is the most common clinic protocol, based on animal studies using local delivery. Oral capsules are also compounded, justified by gastric origin and rodent oral efficacy data, though systemic bioavailability of peptides is generally poor without specialized formulation.

Intranasal and topical routes appear in niche protocols but have less published support. Dosing at 250 mcg twice daily or 500 mcg once daily for 4 to 12 weeks is typical in compounding formularies; evidence-based standardization does not exist.

Human evidence: the gap

As of 2026, peer-reviewed human RCTs for BPC-157 in tendinopathy, muscle injury, or inflammatory bowel disease are scarce. Most human data consists of case reports, small uncontrolled series, and athletic community self-experimentation. A 2025 review in the peptide literature summarized preclinical robustness and called for formal human trials before clinical recommendation.

This does not mean the peptide is inactive in humans. It means the evidence tier is below what physicians typically require for guideline endorsement. Compounding pharmacies and telehealth platforms offer BPC-157 where state law and prescriber judgment allow, with informed consent about off-label, non-FDA-approved status.

What patients use it for

Safety considerations

Animal toxicology suggests wide safety margins, but human long-term safety data are incomplete. Concerns include:

BPC-157 vs. TB-500

TB-500 (thymosin beta-4 fragment) is another recovery peptide with overlapping angiogenic and actin-binding mechanisms. Clinics sometimes alternate or combine them. BPC-157 has richer gastric and tendon literature; TB-500 has more systemic cell-migration framing. Neither has strong human RCT backing for musculoskeletal injury.

Regulatory reality

The FDA has flagged certain peptide bulk drug substances, including some used in compounding, for safety and immunogenicity review. BPC-157's legal status for compounding varies with federal and state rules. Patients should receive product from 503A pharmacies with valid prescriptions, not research-chemical vendors marketing for "laboratory use only."

CLYR Health offers BPC-157 injection for patients whose providers determine an off-label recovery protocol is appropriate, with explicit understanding that evidence is primarily preclinical and individual response is variable.